Tollys
  • About Us
    • Company
    • Board of Directors
    • Management
    • Scientific Advisory Board
  • Science
    • Immuno-oncology
    • TLR3 Science
    • Publications & Posters
  • Product
    • TL-532
    • Intellectual property
  • Pipeline
    • TLR3+ Cancers
  • News
  • Careers
  • Contact
Select Page

Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.).

by SmallStories | Sep 11, 1991 | Publications

Lacour J, Laplanche A, Delozier T, Berlie J, Mourali N, Julien JP, De Gislain C, Namer M, Petit JC, Denis V, et al.

Breast Cancer Res Treat. 1991 Sep;19(1):15-21.

Recent Posts

  • TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
  • Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
  • TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
  • TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
  • TOLLYS : la phase clinique bientôt en vue (La Gazette du Laboratoire – Juillet 2022)

Recent Comments

    Archives

    • October 2022
    • September 2022
    • July 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • October 2020
    • July 2020
    • May 2020
    • December 2019
    • November 2019
    • August 2018
    • June 2016
    • January 2015
    • September 2012
    • March 2011
    • December 2007
    • August 2007
    • April 2006
    • September 1991
    • July 1980

    Categories

    • News
    • Publications

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Design by Small Stories ©2019